Inogen(INGN) ZACKS·2024-11-08 00:10Company Performance - Inogen reported a quarterly loss of $0.25 per share, which was better than the Zacks Consensus Estimate of a loss of $0.51, and a significant improvement from a loss of $1.97 per share a year ago [1] - The company achieved an earnings surprise of 50.98%, having previously been expected to post a loss of $0.54 per share but actually reporting a loss of $0.24, resulting in a surprise of 55.56% [2] - Inogen's revenues for the quarter ended September 2024 were $88.83 million, exceeding the Zacks Consensus Estimate by 6.16% and up from $83.97 million year-over-year [3] Stock Performance - Inogen shares have increased approximately 74.3% since the beginning of the year, outperforming the S&P 500's gain of 24.3% [4] - The current consensus EPS estimate for the upcoming quarter is -$0.55 on revenues of $76.61 million, and for the current fiscal year, it is -$1.92 on revenues of $326.98 million [8] Industry Outlook - The Medical - Instruments industry, to which Inogen belongs, is currently ranked in the top 25% of over 250 Zacks industries, indicating a favorable outlook [9] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Inogen's stock performance [6]